Aiosyn, Radboud University medical centre and Pathologie-DNA have received a €1.3m ($1.4m) EFRO-OOST grant to boost artificial intelligence (AI) technology development for breast and skin cancer diagnostics.
Through the AIRAT project, the three organisations will work together to launch CE-marked deep learning algorithms for automated mitosis detection into the market.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Under the project, Aiosyn will be responsible for the further development and validation of AI-driven algorithms designed for the diagnosis of breast and skin cancer.
Pathologists can precisely predict tumour growth and understand patients’ prognosis using AI-based digital biomarkers.
It helps decrease observer variability and enhance the consistency of diagnoses while improving patient outcomes.
Aiosyn chief innovation officer Wouter Bulten said: “At Aiosyn, we recognise the critical role pathologists play in diagnostics.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Through close collaboration, this EFRO grant enables us to further develop AI tools that support pathologists and enhance pathology practice.”
Aiosyn’s algorithms are set to be integrated into the current digital pathology workflows such as Sectra.
AI-driven solutions are expected to make significant advancements in evaluating and managing cancer patients globally.
Aiosyn CSO and Radboud University medical centre professor Jeroen van der Laak said: “Once you have decided which problem to solve and have collected all required data, developing AI for Pathology is doable.
“But collecting high-quality data is tough and getting the AI to a level that truly creates patient value is even tougher. In our AIRAT project we will tackle those challenges: collect multi-center data and move the developed AI forward to a certified product, ready to support pathologists.”
